Effects of SDZ NVI-085, a putative subtype-selective alpha 1-agonist, on canine cataplexy, a disorder of rapid eye movement sleep.
Canine narcolepsy is an animal model of the human rapid eye movement sleep disorder. Dogs exhibit bouts of sleep attacks and muscle atonia (cataplexy) that are induced by emotions and thought to be abnormal rapid eye movement sleep episodes. We have previously demonstrated that cataplexy is strongly inhibited by increases in noradrenergic activity. This effect is mediated through central alpha 1-adrenoceptors, presumably of the alpha 1B subtype. In this study, we demonstrate with the canine model that SDZ NVI-085, a new compound with alerting effects, is a potent anticataplectic agent that may act through stimulation of an alpha 1-adrenoceptor subtype.
Renaud
A
A
Sleep Research Center, Stanford University School of Medicine, Palo Alto, CA 94304.
Nishino
S
S
Dement
W C
WC
Guilleminault
C
C
Mignot
E
E
D000316:Adrenergic alpha-Agonists / Q000627:therapeutic use*; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D001831:Body Temperature / Q000502:physiology; D001643:Bridged Bicyclo Compounds / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds; D002385:Cataplexy / Q000188:drug therapy* / Q000235:genetics / Q000523:psychology; D004195:Disease Models, Animal; D004285:Dogs; D004435:Eating / Q000502:physiology; D006339:Heart Rate / Q000502:physiology; D009290:Narcolepsy / Q000188:drug therapy*; D010078:Oxazines / Q000627:therapeutic use*; D010988:Play and Playthings; D011224:Prazosin / Q000378:metabolism; D011869:Radioligand Assay; D015016:Yohimbine / Q000378:metabolism
D000316:Adrenergic alpha-Agonists; D001643:Bridged Bicyclo Compounds; D001952:Bridged-Ring Compounds; D010078:Oxazines; C074349:SDZ NVI-085; D015016:Yohimbine; D011224:Prazosin